HIV-1 Infection research hub

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This study is testing a new combination medicine, DOR/ISL, for people newly diagnosed with HIV-1 who haven't started treatment yet. It compares this new medicine to an existing treatment to see if it's as good at reducing the amount of HIV in the body.

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

This study looks at a new two-in-one medicine, Doravirine/Islatravir (DOR/ISL), for people with HIV-1 whose virus is already under control. It wants to see if switching to this new medicine is safe and works as well as their current treatment.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

This study is looking for people with HIV-1 who are currently on a complex treatment plan. It compares a new two-drug combination, bictegravir and lenacapavir, with their current treatment to see if it's a simpler and effective option.

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

This study looks at a new two-drug HIV treatment, Doravirine/Islatravir (DOR/ISL), for people living with HIV-1 who are currently doing well on another common treatment, Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF). Researchers want to see if switching to the new treatment is as effective and safe.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

This study looks at switching HIV-1 positive people who are stable on Biktarvy to a new combination treatment called bictegravir/lenacapavir. We want to see if this new treatment works just as well and is safe.

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

This study is looking at a new once-a-week tablet for people with HIV. It compares switching to this new tablet (islatravir/lenacapavir) with continuing their usual daily treatment (bictegravir/emtricitabine/tenofovir alafenamide). It aims to see if the new weekly tablet is safe and works just as well for people whose HIV is already well controlled.

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

This study is an ongoing look at a two-drug tablet called MK-8591A for people with HIV-1. It's for those already taking this medicine in previous studies to see how safe and effective it is over a longer time.

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

This study looks at a new two-pill HIV treatment combining doravirine and dolutegravir. It aims to see if switching to this simplified treatment is as good and safe as current three-pill treatments for people living with HIV who have their virus under control.

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

This study is looking at a new once-weekly tablet called islatravir/lenacapavir (ISL/LEN) for people living with HIV-1. It compares switching to this new tablet with continuing their current daily HIV treatment to see if it's safe and works well.

An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1

This study is testing new medicines for people recently diagnosed with HIV-1. It compares a weekly pill combining GS-1720 and GS-4182 against a daily pill called Biktarvy. The main goal is to see which treatment best controls the virus.

An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1

This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.

MK-8507 Extended Multiple Dose Study

A Phase IIIb, multi-center, non-randomized, parallel-group, open-label, hybrid type I study evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral dolutegravir/lamivudine once-daily as a first-line regimen followed by participant-determined optional switch to long-acting intramuscular cabotegravir plus rilpivirine every two months for the maintenance of virologic suppression in antiretroviral therapy naive adults living with HIV-1.

A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

The MISTRAL study investigates how gut bacteria affect people living with HIV, especially those over 50. It aims to find ways to improve health, reduce complications like inflammation, and make treatments and vaccines work better by understanding the gut microbiome.